Skip to main content

GOVX

Stock

GOVX

Stock
Health Care
Biotechnology

Performance overview

GOVX Price
Price Chart

Forward-looking statistics

Beta
0.81
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Company info

SectorHealth Care
IndustryBiotechnology
Employees21
Market cap$4.1M

Fundamentals

Enterprise value$12.0M
Revenue$5.6M
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.80
Dividend per share
Revenue per share$0.74
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth
Credit
Liquidity
Inflation
Commodities
Interest Rates

Valuation

Dividend yield0.00%
PEG Ratio-0.56
Price to sales1.37
P/E Ratio-0.56
Enterprise Value to Revenue2.14
Price to book480.10

Upcoming events

Next earnings dayMarch 28, 2025
Next dividend day
Ex. dividend day

News

Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross?

After reaching an important support level, GeoVax Labs Inc. (GOVX) could be a good stock pick from a technical perspective. GOVX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Zacks Investment Research (August 27, 2024)
GeoVax Labs Stock Jumps On US Patent For Malaria Vaccine Candidate

The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's (NASDAQ: GOVX) modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite.

Benzinga (April 26, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free